Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure

Circulation

Volumn 99, Issue 11, 1999, Pages 1422-1425

  Loh, Evan ^a   Rebbeck, Timothy R ^a   Mahoney, Paul D ^a   DeNofrio, David ^a   Swain, Judith L ^a   Holmes, Edward W ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Genes; Heart failure; Survival

Indexed keywords

ADENOSINE MONOPHOSPHATE DEAMINASE; MUTANT PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEART TRANSPLANTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0033596881     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.11.1422     Document Type: Article

References (24)

1. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Burnett JC, Rodeheffer RJ, Chesebro JH, Tazelaar HD. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77-82.
2. Berko BA, Swift EP. X-linked dilated cardiomyopathy. N Engl J Med. 1987;316:1186-1191.
3. Michels VV, Driscoll DJ, Miller FA. Familial aggregation of idiopathic dilated cardiomyopathy. Am J Cardiol. 1985;55:1232-1233.
4. Graber HL, Unverferth DV, Baker PB, Ryan JM, Baba N, Wooley CF. Evolution of a hereditary cardiac conduction and muscle disorder: a study involving a family with six generations affected. Circulation. 1986;74: 21-35.
5. Mestroni L, Miani D, Di Lenarda A, Silvestri F, Bussani R, Filippi G, Camerini F. Clinical and pathologic study of familial dilated cardiomyopathy. Am J Cardiol. 1990;65:1449-1453.
6. Morisaki T, Gross M, Morisaki H, Pongtratz G, Zollner N, Holmes EW. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A. 1992;89:6457-6461.
7. Sabina RL, Holmes EW. Myoadenylate deaminase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Inc; 1995;II: 1769-1780.
8. Sinkeler SPT, Joosten EMG, Wevers RA, Oei TL, Jacobs AE, Veerkamp JH, Hammel BC. Myoadenylate deaminase deficiency: a clinical, genetic, and biochemical study in nine families. Muscle Nerve. 1988;11:312-317.
9. Sabina RL, Swain JL, Olanow CW, Bradley WG, Fishbein WN, DiMauro S, Holmes EW. Myoadenylate deaminase deficiency: functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest. 1984;73:720-730.
10. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Arch Intern Med. 1990;150: 769-773.
11. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2597-2599.
12. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Masatsugu H. Plasma adenosine levels increase in patients with chronic heart failure. Circulation. 1997;95:1363-1365.
13. Fuller R, Maxwell D, Conradson T, Dixon C, Barnes P. Circulatory and respiratory effects of infused adenosine in conscious man. Br J Clin Pharmacol. 1987;24:309-317.
14. Hori M, Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension. 1991;18:565-574.
15. Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res. 1993;27:3-8.
16. Whittaker P, Kloner RA, Przyklenk K. Intramyocardial injections and protection against myocardial ischemia: an attempt to examine the cardioprotective actions of adenosine. Circulation. 1996;93:2043-2051.
17. Toombs CF, McGee DS, Johnston WE, Vinten-Johansen J. Myocardial protective effects of adenosine: infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation. 1992; 86:986-994.
18. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol. 1994;76:5-13.
19. Bouma MG, Stad RK, van den Wildenberg FAJM, Burman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol. 1994;133:4159-4168.
20. Kitakaze M, Hori M, Kamada T. The role of adenosine and its interaction with alpha-adrenoceptor activity in myocardial ischemic and reperfusion injury. Cardiovasc Res. 1993;27:18-27.
21. Hori M, Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension. 1991;18:565-574.
22. Kitakaze M, Hori M, Kamada T. The role of adenosine and its interaction with alpha-adrenoceptor activity in myocardial ischemic and reperfusion injury. Cardiovasc Res. 1993;27:18-27.
23. Gho BCG, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. Circulation. 1996;94:2193-2200.
24. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of gastrocnemius muscle in the rabbit. Circulation. 1997;96:1641-1646.